David E. Cohen, a director at Evommune, Inc. (NASDAQ:EVMN), executed several transactions involving the company's common stock in early June 2026. According to filings with the Securities and Exchange Commission (SEC) Form 4, Cohen sold common shares totaling $123,093 on June 2, 2026.
These sales were conducted under the framework of a Rule 10b5-1 trading plan that Cohen established on March 3, 2026. The total disposition involved 6,056 shares of common stock. These shares sold across various price points, ranging from $20.21 to $21.38 per share. Following the execution of these sales, David E. Cohen's direct holdings of Evommune common stock amount to 17,609 shares.
The timing of this sale is noteworthy when considering the recent performance metrics for Evommune. As reported in the filings and associated data, Evommune’s stock was trading at $19.73, reflecting a decline of 15% over the preceding week. While the company currently maintains a market capitalization valued at $713.88 million, its financial standing remains unprofitable, reporting earnings per share (EPS) of -$5.36 over the last twelve months.
Beyond the stock sales, the SEC filings also confirm that Cohen acquired 15,673 stock options on the same date. These derivative securities grant him the right to purchase common stock at an exercise price of $19.82 per share. The expiration date for these options is set for June 1, 2036.
The vesting schedule for the shares underlying these acquired options stipulates that they will vest upon the earlier occurrence of two events: either the first anniversary of the grant date or the date of Evommune’s next annual meeting of stockholders. This vesting is contingent on Cohen maintaining continuous service through the scheduled vesting date.
These recent transactions by a key director are situated against a backdrop of positive operational and financial developments for Evommune, Inc. In separate news reports, the company announced its first-quarter financial results. During this period, Evommune reported a loss of $0.64 per share. This outcome was better than analyst expectations, which had projected a loss of $0.76 per share.
Furthermore, H.C. Wainwright reiterated an investment rating on the company, maintaining a Buy recommendation and setting a price target of $50. The investment firm's positive outlook highlighted specific progress in the company’s clinical pipeline. Specifically, they noted the completion of enrollment for the Phase 2b dose-ranging trial targeting moderate-to-severe chronic spontaneous urticaria. This particular trial is designed to evaluate three distinct EVO756 dose regimens alongside a placebo. The primary objective measured for this study is the change in UAS7 at Week 12, and these results are anticipated to guide both the design and the optimal dose selection for subsequent Phase 3 trials.
The combination of director activity, quarterly financial performance that surpassed negative expectations, and positive analyst coverage tied to clinical trial advancement provides a comprehensive view of Evommune's ongoing efforts in both its commercialization path and its advanced research programs. The stock data also provided context on the current trading range, showing recent fluctuations between $19.41 and $20.10.